Guildford's Ergomed confident in future growth prospects

Guildford based service provider to the pharmaceutical industry Ergomed expects growth to continue, despite industry headwinds, following its successful financial year in 2022.

This confidence has largely been inspired by new CFO of the company Jonathan Curtain, who joined in January 2023. Jonathan's experience in finance and investor relations, brought from his previous role as Senior Vice President of Finance at Icon PLC, has helped him oversee the continued growth of the company.

Read more - Guildford’s Ergomed PLC report £27m revenue increase in 2022

Jonathan said: ''Overall we're very pleased with the continued progress that we made during 2022. We saw another strong year of revenue growth in both our CRO and Pharmacovigilance divisions. We're up 23 per cent at a group level, to a £145.3 million in line with our market expectations.

''This is all at a time when there have been wider industry and global macro economic headwinds.

''From an operational perspective we've completed our most recent acquisition, ADAMAS, in February last year which was integrated successfully. We also saw the largest market for our services, which is in the US, grow to make 62 per cent of our revenues and we will look to continue to invest in that area going forward.

''Finally, the strengthening of our board and management teams with the appointments of John Dawson, Anne Whitaker, and Michael Spiteri set us up for continued success going into the future.''

Read more - Oxford Nanopore Technologies posts full-year revenues of £200m